罕见浆细胞样变异型前列腺癌177Lu-PSMA治疗后68Ga-PSMA PET/CT显示异常应答
Exceptional Response of Rare Plasmacytoid Variant Prostate Cancer Post 177Lu-PSMA Therapy Seen on 68Ga-PSMA PET/CT.
PubMed 文献 · Clin Nucl Med · 2022-10-26
本文报道一例罕见浆细胞样变异型腺泡型前列腺腺癌患者,该变异型侵袭性强、对激素治疗无反应且总体预后差。治疗前和治疗后68Ga-PSMA PET/CT图像显示,患者对177Lu-PSMA治疗出现异常应答,提示68Ga-PSMA PET/CT可用于评估肿瘤PSMA亲和性,177Lu-PSMA治疗在这类患者中具有潜力。
要点
- 浆细胞样变异型前列腺癌侵袭性强、对激素治疗无反应且预后差。
- 68Ga-PSMA PET/CT可用于评估该变异型肿瘤的PSMA亲和性。
- 治疗后图像显示该患者对177Lu-PSMA治疗出现异常应答。
核心结论
- 本病例显示68Ga-PSMA PET/CT可用于评估肿瘤PSMA亲和性,且177Lu-PSMA治疗在这类患者中具有潜力。
研究设计与样本
- 本文为病例报告,呈现一例罕见浆细胞样变异型腺泡型前列腺腺癌患者治疗前和治疗后的68Ga-PSMA PET/CT图像。
主要发现
- 治疗前和治疗后68Ga-PSMA PET/CT图像显示该患者对177Lu-PSMA治疗出现异常应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Plasmacytoid is a rare variant of acinar prostatic adenocarcinoma. The aggressive type is characterized by an aggressive clinical course, lack of responsiveness to hormonal therapies, and an overall poor prognosis. Here we present pretherapy and posttherapy 68Ga-PSMA PET/CT images showing an exceptional response to 177Lu-PSMA therapy. This case demonstrates the usefulness of both 68Ga-PSMA PET/CT in assessing the tumor PSMA avidity and the potential of 177Lu-PSMA therapy in these patients.
来源:Clin Nucl Med,查看原文。版权归原作者所有。
引用
- Maharaj M, Heslop L, Govender T, et al. Exceptional Response of Rare Plasmacytoid Variant Prostate Cancer Post 177Lu-PSMA Therapy Seen on 68Ga-PSMA PET/CT. Clin Nucl Med. 2022. PMID: 36607375. doi:10.1097/RLU.0000000000004473
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。